• Prognosis and course in schizophrenia emerged as a central research focus, with emphasis on short illness duration, onset type, exogenic precipitating factors, early symptomatology, and potential for remission or deterioration across diverse clinical settings [1], [8], [13], [10], [19], [18].

• Neurophysiological investigations framed schizophrenia around brain activity patterns, using electroencephalography and cortical dysrhythmias as potential constitutional/biological markers, sparking debates on normal vs abnormal EEG signatures [4], [5], [16], [2].

• Pharmacological and biological treatment explorations sought causal links and therapeutic potential through convulsive therapy, nicotinic acid, and biochemical disturbances, signaling early psychopharmacology's role in schizophrenia [6], [9], [12], [2].

• Cognitive, perceptual, and behavioral studies traced how schizophrenia disrupts abstract reasoning, imagery, environmental accessibility, and overall thinking patterns, highlighting cognitive deterioration as a core feature [3], [7], [11], [19], [20].

• Diagnostic conceptualizations and risk stratification emerged through genetics, differential diagnosis, and developmental considerations, arguing for layered classification and predictive frameworks in schizophrenia [17], [15], [11], [20].